Exploring trends in antibiotic use and resistance in a district, regional and tertiary hospital in the uMgungundlovu District. by Desai, Ayesha.
Exploring Trends in Antibiotic Use and Resistance in a District, Regional and 
Tertiary Hospital in the uMgungundlovu District. 
 
By 
 
 Ayesha Desai  
 
 
 
 
Submitted in fulfilment of the academic requirements for the degree of Master of 
Pharmacy in the discipline of Pharmaceutical Sciences in the School 
of Health Sciences, University of KwaZulu-Natal, Durban. 
 
 
Supervisors 
Professor Sabiha Yusuf Essack 
Professor Fatima Suleman 
 
21 December 2017 
  
 
  
ii 
EXPLORING TRENDS IN ANTIBIOTIC USE AND RESISTANCE IN A 
DISTRICT, REGIONAL AND TERTIARY HOSPITAL IN THE 
UMGUNGUNDLOVU DISTRICT.  
 
21 December 2017 
 
 
AYESHA DESAI 
 
216073235 
 
A dissertation submitted to the School of Health Sciences, College of Health Science, 
University of KwaZulu-Natal, Westville Campus, for the degree of Master of Pharmacy 
(Pharmacy Practice). 
 
This is the dissertation in which the research is presented as a discrete research publication, 
with an overall introduction and final summary. 
 
This is to certify that the content of this dissertation is the original research work of Miss 
Ayesha Desai. 
 
As the candidate’s supervisor, I have approved this thesis for submission. 
 
Supervisor: 
 
Signed: -------------------------- Name: Prof Sabiha Y. Essack Date: ---------------- 
 
 Signed: -------------------------- Name: Prof Fatima Suleman      Date: ---------------- 
  
 
  
iii 
DECLARATION 
 
I Ayesha Desai declare that 
1. The research reported in this dissertation, except where otherwise indicated, is my original 
research. 
2. This dissertation has not been submitted for any degree or examination at any other 
university. 
3. This dissertation does not contain other persons’ data, pictures, graphs or other 
information, unless specifically acknowledged as being sourced from other persons. 
4. This dissertation does not contain other persons’ writing, unless specifically 
acknowledged as being sourced from other persons. Where other written sources have 
been quoted, then: 
a. Their words have been re-written and the general information attributed to them 
has been referenced. 
b. Where their exact words have been used, their writing has been placed within 
quotation marks, and referenced. 
5. This dissertation does not contain text, graphics or tables copied and pasted from the 
Internet, unless specifically acknowledged, and the source being detailed in the 
dissertation and in the References section. 
 
Signature: ……………………… 
  
  
Date: 21 December 2017………………… 
 
  
 
  
iv 
ACKNOWLEDGMENTS 
 
First and foremost all praise is due to God the Giver of knowledge. Without His grace none of 
this would have been possible.  
 
I appreciate all the advice, efforts, guidance and unwavering support provided throughout this 
journey by both my supervisors, Professor Sabiha Yusuf Essack and Professor Fatima 
Suleman.  
 
I acknowledge the Head of Pharmaceutical Services of KwaZulu-Natal, Mister Vusi Dlamini, 
without his approval of the study I would not have been able to go ahead with my research – 
for this I am grateful to him.   
 
The Department of Health of KwaZulu-Natal kindly provided antibiotic usage records. 
 
I would like to extend my gratitude to Dr Sue Candy of the National Institute for 
Communicable Diseases who provided the microbiology data from the district’s hospitals 
required for the study. 
 
I would like to acknowledge and thank the National Research Fund (NRF) through which I 
received a scholarship to carry out this study. It is through their financial support that I was 
able to apply for and carry out a Master’s degree.  
 
I am grateful to these people that assisted me in achieving my goal of successfully completing 
my Master’s degree. I am indebted to each and every one mentioned above for the support 
rendered.  
 
  
 
  
v 
LIST OF ABBREVIATIONS 
 
CDC      Center for Disease Control and Prevention 
E. coli     Escherichia coli 
EML     Essential Medicines List 
GAP     Global Action Plan 
HGT     Horizontal Gene Transfer 
IPC     Infection, Prevention and Control 
MRSA     Methicillin Resistant Staphylococcus Aureus 
MSSA     Methicillin Susceptible Staphylococcus Aureus 
NDoH     National Department of Health 
NHLS     National Health Laboratory Service 
NICD     National Institute for Communicable Diseases  
SAASP     South African Antibiotic Stewardship Programme 
S. aureus    Staphylococcus aureus 
STG     Standard Treatment Guideline 
 
 
  
 
  
vi 
ABSTRACT 
 
Antibiotics play an important role in overcoming life-threatening bacterial infections. 
However, the increasing rate of antibiotic resistance is a serious threat to public health. 
Undoubtedly the indiscriminate use of antibiotics plays a role in the emergence of resistance. 
The objective of this study was to identify the trends in antibiotic use and resistance at three 
public sector hospitals at three different levels of healthcare in the uMgungundlovu district, 
i.e., a district hospital, a regional hospital and a tertiary hospital. The antibiotics indicated for 
the treatment of infections caused by Escherichia coli (Gram-negative bacteria) and 
Staphylococcus aureus (Gram-positive bacteria) were investigated. Yearly antibiotic 
consumption data was calculated as Defined Daily Dose (DDD) per 1 000 inhabitants and 
percentage susceptibility was analysed based on susceptible and non-susceptible isolates for 
each antibiotic. There was a general trend of reduced antibiotic susceptibility as the levels of 
healthcare increased attributed to the fact that more severe and complex infections are treated 
at the higher levels of healthcare and require greater quantities of and/or broader spectrum 
antibiotics. For treatment of infections caused by S. aureus antibiotic use generally increased 
as the level of healthcare increased. Azithromycin was the most frequently used while 
linezolid was the least used antibiotic and showed the highest levels of susceptibility across 
all levels of healthcare. S. aureus showed the lowest level of susceptibility to cloxacillin 
across all the levels of healthcare and was indicative of the prevalence of methicillin-resistant 
S. aureus (MRSA). When antibiotic use was correlated with resistance, cloxacillin displayed 
a downward trend in use from 2014 to 2016 while cloxacillin resistance increased from 2014 
to 2015 followed by a decrease in resistance in 2016 indicating that resistance is a function of 
time and use and that the lag time between the decrease in use and a corresponding decrease 
in resistance is not predictable and varies for different antibiotics in different healthcare 
settings. In contrast, azithromycin showed a steady decline in resistance although use 
increased over the three years (2014-2016).  In the case of the treatment of infections caused 
by E. coli there was a general trend of the greater use of narrow spectrum antibiotics at the 
lower district and regional levels while the broad-spectrum antibiotics were used more 
frequently at a tertiary level. Trimethoprim-sulphamethoxazole was used the most, whereas 
colistin was used the least. Contrary to expectations, there were higher susceptibility levels to 
third and fourth generation cephalosporins and meropenem at a tertiary level than regional 
level. E. coli showed lowest levels of susceptibility to ampicillin and highest level of 
susceptibility to levofloxacin across all levels of healthcare.  When antibiotic use was 
correlated with resistance, antibiotics that were used frequently (sulphamethoxazole-
trimethoprim, amoxicillin clavulanic acid and ampicillin) displayed high levels of resistance 
over the three years. Trimethoprim-sulphamethoxazole use decreased slightly over the years 
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however resistance remained high. The same trend was observed with amoxicillin clavulanic 
acid and ampicillin use and resistance indicating possible co-selection of resistance by the use 
of other classes of antibiotics. This study added to the body of knowledge that there exists a 
link between the use of antibiotics and resistance, albeit not a direct causal one. Quantifying 
antibiotic use and identifying trends in resistance associated with antibiotic consumption 
assists prescribers and policy makers to improve antibiotic use, guide antibiotic stewardship 
programmes and optimise antibiotic policies and guidelines. 
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   CHAPTER 1. INTRODUCTION AND LITERATURE REVIEW 
 
1.1 INTRODUCTION 
 
Antibiotics are agents that kill or inhibit the growth of bacteria. Soil bacteria or fungi produce 
them naturally. The exposure of antibiotics to bacteria causes the microbes to either die or 
adapt. Thus antibiotic resistance occurs through these protective, adaptive bacterial 
mechanisms (Microbiology Society, 2017). The development of antibiotics dates back to 
between 1937 and 1940. Those were the years, in which the discovery of sulphonamides and 
penicillin (the first two usable antibiotic agents) revolutionized medicine in many aspects. 
The development of antibiotics was considered “a turning point in human history” (Davies & 
Davies, 2010). Antimicrobial agents became widely available and accessible and were used to 
treat common infections, many of which were not caused by bacteria. In 1945, during an 
interview with the New York Times, Sir Alexander Fleming (the scientist who discovered 
penicillin) said that based on laboratory research he had conducted, the inappropriate use of 
penicillin could lead to resistant mutant forms of Staphylococcus aureus. True to his word – 
bacterial resistance to the antibiotic was witnessed at a phenomenal rate. During the first year 
of use of penicillin a number of strains of S. aureus had become resistant to the antibiotic 
(Alanis, 2005). Resistance was thought to be a problem pertaining to hospitalised patients 
only. However, resistance was soon recorded in the outpatient setting where resistant bacteria 
contributed to the development of community-acquired infections (Alanis, 2005). Newer 
antibiotics were required to overcome the resistance that had developed and this led to the 
development of several other antibiotic classes. Over time there have been over 17 classes of 
antibiotics that were discovered and produced. However, bacteria have developed one or 
more resistance mechanisms against each class over time (Davies & Davies, 2010).  
 
Resistance itself is costly to governments and patients, and is threatening the effectiveness of 
health delivery worldwide. The pipeline of drug discovery is not optimal and the incentive to 
develop new antibiotics is reduced (WHO, 2001). The discovery of new antibiotics declined 
from the 1990s. The Food and Drug Administration (FDA) of America gave 29 new 
approvals for antibiotics during the 1990s while the first decade of the 2000s saw only 9 new 
approvals (The PEW Charitable Trusts, 2016). Shareholders of pharmaceutical companies 
that undertake the development of new medicines expect high returns on their investments in 
these companies. New antibiotic development is increasingly expensive and in many cases 
may require 10-14 years for approval for clinical use followed by 20 years of patent life. 
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Globally there has been a reduction in cost effective and quality assured novel therapeutic 
agents (Alanis, 2005).  
 
All antibiotics need to be conserved.  One way of doing so is by using newer and broad-
spectrum antibiotics sparingly. This does however lead to a domino effect. The restriction on 
sales and use of novel antibiotics will lead to a decrease in the generation of revenues. This in 
turn leads to a decrease in the interest and investment in research and development. There is 
the proposed model of delinking profits from product sales and pharmaceutical return on 
investment to try and tackle the growing concern of reduced investment in antimicrobial 
research and development (Outterson et. al., 2016). Scientific barriers in medicine discovery, 
regulatory challenges and decreased returns on investments have led to pharmaceutical 
companies scaling down on antibiotic research (The PEW Charitable Trusts, 2016).  There is 
the need for the continuous discovery of novel antibiotics. Interventions are also required to 
slow down and contain the progression of antibiotic resistance using a multi-disciplinary 
approach (Ndihokubwayo et. al, 2013).  Diverse, multi-faceted strategies need to be explored 
in order to contain the escalating antibiotic resistance challenge.  
 
The development of antibiotic resistance can be attributed to the indiscriminate use of 
antibiotics in human, animal and environmental health by human beings and resistance may 
thus be seen as a man-made situation that has been “superimposed on nature” (Lewis, 2013). 
The excessive use of antibiotics has exerted selection pressure and has contributed to the 
emergence of resistance that has reached unprecedented levels globally. In the presence of an 
antibiotic the microbes find methods of adaptation, becoming resistant. The resistant bacterial 
cell multiplies conferring resistance onto subsequent cells (Microbiology Society, 2017).   
 
National antibiotic resistance containment policies and stewardship programmes need to be 
continually revised and implemented in the healthcare system, to optimize antibiotic use with 
an overall aim of reducing use, in order to attempt to contain antibiotic resistance. Optimizing 
the use of antimicrobials is one of the strategic objectives of the Global Action Plan (GAP) on 
Antimicrobial Resistance formulated by the tripartite alliance of the World Health 
Organization (WHO), the Food and Agriculture Association of the United Nations (FAO) and 
the Organization for Animal Health (OIE). Objective 4 of the GAP speaks to optimizing the 
use of antimicrobial medicines in both human and animal health. WHO recognizes the need 
for evidence-based prescribing and dispensing of antibiotics. There is a dearth of data on 
antibiotic use in humans from lower-income countries (World Health Organization, 2014).   
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In order for evidence-based strategies to be developed, monitoring of antibiotic use and 
prescribing patterns need to be conducted to track the nature and extent of antibiotic use, 
specifically misuse, overuse and/or underuse of such agents.  One such way is through 
adopting medicine utilization studies within health facilities. The ultimate goal of a medicine 
utilization study is to assess whether therapy is rational or appropriate. One way of 
representing medicine utilization is by calculating defined daily doses (DDDs). DDD is a 
statistical measure of medicine consumption defined by the WHO Collaborating Centre 
(WHOCC) for Drug Statistics. Figures are presented as number of DDDs per 1 000 
inhabitants per day for outpatients and as number of DDDs per 100 bed-days for inpatients 
(WHO, 2003). DDD is a unit of measurement that is independent of the price of the medicine 
and is used by researchers to analyse trends in medicine consumption allowing for 
comparisons between different medicines and/or different health environments (WHO, 2011). 
The unit of measurement has been used since the early 1970s and has been found suitable for 
medicine utilization comparisons to be made nationally and internationally, to evaluate long-
term trends in medicine use and to assess the impact of certain events in healthcare on 
medicine use.  DDDs further provide denominator data in investigating medicine safety 
(WHO, 2011). 
 
This comparative study quantified antibiotic consumption in terms of defined daily doses per 
1 000 inhabitants (DDDs) by using central pharmaceutical stores depot issuing data obtained 
for three hospitals at different levels of care, i.e., district, regional and tertiary. Trends in 
antibiotic susceptibility at the three levels of healthcare were also explored using 
microbiology data from existing databases at the hospitals in question. DDDs per 1 000 
inhabitants were then correlated with antibiotic resistance patterns. This allowed basic 
comparisons on antibiotic consumption and resistance between health care facilities at 
different levels of healthcare deliver. 
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1.2 LITERATURE REVIEW 
 
1.2.1 Antibiotic Resistance: A Global Public Health Concern 
 
In the presence of antibiotics, bacteria are either killed or carry resistant genes that enable 
them to survive. The surviving bacteria then replicate, sometimes at a rapid speed. These 
replicated bacteria then become the dominant microbes within their population leading to 
sustained resistance. The misuse, overuse and/or inappropriate use of antibiotics are drivers 
for the development and escalation of antibiotic resistance (NIH, 2011).  
 
The Antimicrobial Resistance Review Report commissioned by the government of the United 
Kingdom both analyses antibiotic resistance as a global problem and proposes steps that can 
be taken to tackle the problem (O’Neil, 2014). The report highlighted the alarming evidence 
of global resistance: 
 99 000 deaths occur each year in the United States (US) which are caused by hospital 
acquired infections from resistant bacteria. 
 Antimicrobial resistant organisms account for 25 000 deaths per year in Europe. 
 In a developing country like Pakistan, resistant bacteria cause 71% of neonatal 
infections. 
 The majority of hospital infections in Peru and Bolivia are due to antimicrobial 
resistant bacteria.  
O’Neil (2014) posits that if antimicrobial resistance is neglected, it is estimated that by the 
year 2050 more than 10 million people will die per year due to resistant infections. 
 
In 2012 Kinmang’a conducted a situational analysis of antimicrobial resistance in Africa on 
the premise that the influx of large quantities of antibiotics entering African countries through 
the advancement of technology and resources has the potential to promote antibiotic 
resistance and cause lifesaving medicines to become ineffective. With the use of PubMed 
online database, 103 articles were sourced. Research articles on antimicrobial resistance in 
African countries were analysed. Root-causes of antimicrobial resistance were identified this 
included the lack of human resources in the healthcare sector in sub-Saharan Africa, 
inadequate laboratory facilities coupled with inadequately trained staff to isolate pathogens 
and perform sensitivity tests leading to non-evidence-based empirical treatment of infectious 
diseases. The study argued that empirical treatment contributed to the emergence of resistant 
strains of bacteria as many African countries lacked adequate guidelines to ensure good 
prescribing practices. There was insufficient local data to assist in promoting antibiotic 
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stewardship programmes in healthcare facilities (Kinmang’a, 2012). This situational analysis 
helps us to recognise that antimicrobial resistance is a growing problem in developing 
countries and more specifically on the African continent.  
 
1.2.2 The Development of Antimicrobial Resistance  
 
The development of resistance is a consequence of selection pressure which occurs when the 
use of antimicrobial agents applies “selection pressure” by killing the susceptible bacteria 
thus allowing resistant microorganisms to survive and thrive. There are two main types of 
resistance. The first type is intrinsic (innate or inherent) resistance and the second type is 
acquired resistance. 
 
1.2.2.1 Intrinsic Resistance 
 
This is an innate ability of the bacterial species to withstand activity of the antimicrobial 
agent on the microorganism. It is often resistance that is developed by the bacterial population 
prior to use by the human population (Martinez, 2009). Thus this type of resistance is 
independent of antimicrobial exposure. Such resistance includes “lack of affinity of the drug 
for the bacterial target, inaccessibility of the drug into the bacterial cell, extrusion of the drug 
by chromosomally encoded active exporters (efflux pump), and, innate production of 
enzymes that inactivate the drug” (Michigan State University, 2011).  For example, 
vancomycin resistance in Gram-negative bacteria is as a result of the inability of the antibiotic 
molecule to penetrate the Gram-negative outer membrane (Holmes et al., 2015). Another 
example is mycoplasmas that do not have an outer cell wall and are therefore intrinsically 
resistant to β-lactams and glycopeptides as they target the cell wall (Reygaert, 2016).  
Knowledge on this form of resistance is important to prevent inappropriate and/or ineffective 
treatment.  
 
1.2.2.2 Acquired Resistance 
 
In contrast, acquired resistance is where isolates, which were previously susceptible, acquire 
mechanisms of resistance. There is a change in the genetic composition of the bacteria 
resulting in a previously effective antimicrobial agent being rendered in-effective (Stokowski, 
2010).  Acquired resistance involves a selection process (Holmes et al., 2015). Some 
examples of acquired resistance are as follows: 
 Drug inactivation: Bacteria acquire gene-encoded enzymes such as β-lactamases that 
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inactivate or destroy the antimicrobial agent before they reach the target site.  
 Cell wall changes:  Mutations in genes responsible for outer membrane porin regulation 
or expression render the outer membrane impermeable to the antimicrobial agent.   
 Bypass targets:  Mutations in the bacterial DNA change the target enzyme in a metabolic 
pathway resulting in bypassing of the primary target site (Stokowski, 2010).  
1.2.3 Global Action Plan on Antimicrobial Resistance 
 
In May 2014 the World Health Assembly (WHA) endorsed the development of the “Global 
Action Plan on Antimicrobial Resistance” (GAP) by the WHO. It is an action plan that forms 
a basis for countries to develop and improve their own national action plans for the 
containment of antibiotic resistance. The primary goal of the GAP is to achieve the successful 
treatment and, where possible, prevention of infectious diseases. This is to be achieved by 
encouraging the responsible use of quality assured medicines and improved accessibility to 
those in need of them. There are five strategic objectives outlined in the GAP: 
1. “To improve awareness and understanding of antimicrobial resistance through effective 
communication, education and training. 
2. To strengthen the knowledge and evidence base through surveillance and research. 
3. To reduce the incidence of infection through effective sanitation, hygiene and infection 
prevention measures. 
4. To optimize the use of antimicrobial medicines in human and animal health. 
5. To develop the economic case for sustainable investment that takes account of the needs 
of all countries and to increase investment in new medicines, diagnostic tools, vaccines 
and other interventions.” (World Health Organization, 2015)  
 
Strategic objective 2 addresses the need for surveillance. Knowledge can be strengthened 
through an inter-disciplinary approach. Co-operation from national government, 
intergovernmental organizations, along with non-governmental organizations, industry and 
academia play a pivotal role in generating knowledge through surveillance and research. 
Research is imperative in understanding and supporting the implementation of objectives one, 
three and four. Studies must include effective antimicrobial stewardship programmes in the 
one health approach. WHO has identified some of the gaps in knowledge as being: 
1. Lack of knowledge on incidence, prevalence and pathogenic and geographical 
patterns concerning antibiotic resistance. Such information should be promptly 
available in order for evidence based diagnosis and treatment of patients to take 
place. This knowledge will also assist in guiding local, national and regional 
policymaking and subsequently the effectiveness of the interventions can be 
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monitored.   
2. There is the need for improved understanding of how resistance is spread within and 
between humans, animals and agriculture. Furthermore, researchers need to stay 
abreast on emerging resistance and the underlying mechanisms involved. There is the 
need for the rapid characterization of newly emerging resistance and the 
understanding of the underlying mechanisms. This will assist in ensuring that 
surveillance and diagnostic methods and tools are kept up to date. Investment in 
research and development thus needs to be encouraged (World Health Organization, 
2014). One example is that of the WHO Regional Office for Africa development of a 
guideline for assisting countries in establishing and/or improving laboratory-based 
surveillance. The guideline highlights the components required for laboratory-based 
surveillance and subsequent steps involved in establishing these facilities. There are 
steps provided for antimicrobial resistance surveillance of meningitis, bacteraemia 
and enteric epidemic-prone diseases (World Health Organization, 2013). 
Implementation of the guideline will encourage evidence-based prescribing of 
antibiotics and will also assist in creating a surveillance database reference that is 
regionally specific. The application of evidence-based prescribing will also lead to 
optimization of antibiotic use.  
3. A greater degree of research needs to be done on treatment and prevention of 
prevalent bacterial infections. This knowledge is required especially in low resource 
settings. 
4. Research from translational studies need to be used in treatment development, 
diagnostic tools, vaccines amongst other primary interventions.  
5. In agriculture and aquaculture – alternatives to non-therapeutics uses of antibiotics 
have to be identified. 
6. Costs involved in the antimicrobial resistance pandemic as well as the costs versus 
benefits of the Global Action Plan need to be weighed and assessed. 
When it comes to antibiotic resistance in pathogens of major public health concern there are 
several inconsistencies. There are no internationally recognised standards for the collection of 
data and reporting thereof on resistance in humans. Furthermore, there is no suitable forum 
for the sharing of surveillance data globally. There is also the need for agreed upon standards 
across medical, veterinary and agricultural sectors. In 2013, European Union Member States 
had published a strategic research agenda. The WHO encourages the use of the agenda as a 
preliminary framework for the development of a global strategic research agenda.   
 
Strategic objective 4 of the GAP speaks to the optimizing of antimicrobial medicines in both 
human and animal health. Antibiotic use in humans, animals and agriculture is increasing 
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rapidly (World Health Organization, 2014). If the indiscriminate use of antibiotics is not 
addressed, it is estimated that within 35 years, drug-resistant bacterial infections will result in 
10 million deaths annually. Africa and Asia will account for 4.1 and 4.7 million of these 
deaths respectively (Mendelson & Matsoso, 2015). 76% of the global increase in antibiotic 
use during the years 2000 – 2010 is collectively attributable to BRICS (Brazil, Russia, India, 
China, South Africa) (Boeckel et. al, 2014). The increasing use of antibiotics can be 
attributable to over-prescribing, over the counter sales and in some countries antibiotics are 
widely available via the Internet. Regulations surrounding the distribution, quality and use of 
antibiotics need to be strengthened. Relevant stakeholders must be encouraged to invest in 
research and development. Healthcare workers need to be more vigilant when it comes to the 
prescribing and dispensing of antibiotics. It is important for them to identify the source of 
infection and not be subject to patient pressure to prescribe antibiotics unnecessarily. Sub 
optimal patient and health care provider compliance, substandard antibiotics in humans and 
veterinary practice coupled with the inappropriate or unregulated use of antibiotics are 
contributing factors to growth of antibiotic resistance. Regulations have to be strictly 
enforced. The standard of care should be primarily evidence based prescribing and 
dispensing. Therefore countries need to invest wisely in effective, rapid and affordable 
diagnostic tools to encourage evidence-based prescribing in human and animal health (World 
Health Organization, 2014).  
 
1.2.4 South African Antimicrobial Resistance Framework 
 
After much focus was placed on antimicrobial resistance at the WHA in 2014, in October 
2015 the National Department of Health (NDoH) in collaboration with the South African 
Antibiotic Stewardship Programme (SAASP) held a summit for the adoption of an 
Antimicrobial Resistance National Strategic Framework (Brink, 2015). The Director General 
of Health, Precious Matsoso highlighted that in 2013, in South Africa, there was a case of 
multi-drug resistant (MDR) Klebsiella pneumoniae that was found to be resistant to all 
available antibiotics. In South Africa susceptibility data for the period 2012 to 2014 showed 
that resistance in K. pneumoniae to third generation cephalosporin was 32%, while 
fluoroquinolone resistance increased from 28-30% in 2013 (Faure, 2015). This emphasizes 
the urgent call to act upon antimicrobial resistance.  The national strategic framework sheds 
light on the drivers of resistance. It talks of the unnecessary high quantities of antibiotics 
being used.   Prescribers rely heavily on broad-spectrum antibiotics as opposed to 
streamlining treatment with narrow-spectrum, bacteria-specific antibiotics. The goals of the 
national strategy are: 
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1. To define the principles and short to medium term interventions needed to preserve 
the effectiveness of antimicrobials for future generations. 
2. To improve the appropriate use of antibiotics in human and animal health;  
3. To improve the effective management of antibiotic resistant organisms and to prevent 
their transmission. 
4. To create an enabling environment for the successful and sustainable implementation 
of the strategic objectives (National Department of Health, 2014). 
 
The goals are then followed by four strategic objectives: 
 
1. Strengthen, coordinate and institutionalise interdisciplinary efforts.  
2. Optimise surveillance and early detection of antimicrobial resistance.  
3.  Enhance infection prevention and control.  
4. Promote appropriate use of antimicrobials in human and animal health (National 
Department of Health, 2014).  
 
When reviewed broadly, the strategic objectives focus on surveillance, infection prevention 
and control (IPC) and antimicrobial stewardship. Surveillance incorporates national 
surveillance of resistant bacteria, antimicrobial use, medication error reporting structures and 
antimicrobial quality. Monitoring and improving of IPC must be carried out in both the 
community and at hospital level. Antimicrobial stewardship is grounded by policies and 
protocols, which include formulary restrictions, antimicrobial pre-authorisation and 
prescription forms and national prescribing guidelines. Stewardship in terms of point of care 
encompasses performing the correct diagnosis coupled with the correct choice of 
antimicrobial given at the optimum dose. Prescribers also need to de-escalate and discontinue 
antimicrobial agents when it is safe and advisable to do so.  There are strategic enablers 
underpinning these objectives and are as follows: 
 
1. Legislative and policy reform for health systems strengthening – Policies need to set 
the minimum standards for health care quality systems and processes. In animal 
health, stringent control over the use of antibiotics needs to be implemented.  
2. Education – Antimicrobial resistance strategies should be encompassed in the student 
curricula of all healthcare and allied healthcare professionals. Continuing 
Professional Development (CPD) programmes should include antimicrobial 
resistance and the importance of antimicrobial stewardship. Public health drives and 
campaigns must be held to create awareness and improve the understanding 
surrounding antimicrobial resistance. 
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3. Communication – Patient advocacy, introducing the topic in the media and partnering 
with industry are recommended.  
4. Research - Translational research should be encouraged and adopted in improving 
and creating diagnostic tools, antimicrobial stewardship interventions and IPC 
(National Department of Health, 2014.  
 
The overall purpose of the National Antimicrobial Resistance Framework is to serve as a 
guideline in managing antimicrobial resistance. It highlights actions incumbent upon the 
NDoH and all other relevant stakeholders to limit resistant microbial infections and to 
improve and achieve optimal patient care (National Department of Health, 2014). 
 
1.2.5 Surveillance of Antibiotic Use and Resistance.  
 
When formulating an effective response to antibiotic resistance it is important to assess the 
scope of the problem. One such way is through surveillance. Moreover, the importance of 
surveillance is acknowledged and highlighted as an objective in both the GAP and the South 
African Antimicrobial Resistance Framework. Surveillance includes the collecting and 
analysing of data. This, in the healthcare setting, allows for the monitoring and detection of 
possible threats and outbreaks. In turn this will assist in generating an action plan to reduce 
and/or prevent future health threats. Surveillance of resistance data includes having access to 
microbiology laboratory susceptibility data of isolated bacteria. This would also provide 
information on the extent of resistance identified in the bacterial species or identified isolates. 
Changes in resistance patterns can also be monitored over time. In England, hospital 
laboratories are encouraged to upload their microbiology sensitivity data to a national 
database (Johnson, 2015). The system focuses on capturing trends of resistance in S. aureus, 
Enterococci, Streptococcus pneumoniae, P. aeruginosa, E. coli, K. pneumoniae and 
Enterobacter species. This information is then readily available. It is a large amount of useful 
data collected on a continuous basis and also provides a vast geographical coverage of 
information (Johnson, 2015). In United States of America’s (USA), the White House’s 
National Strategy to Combat Antibiotic-Resistant Bacteria talks to the importance of 
surveillance. Analysing and reporting of antibiotic resistant bacteria is important for 
evidence-based decisions to be made. Surveillance data should be available for each country 
as well as globally (Washington, 2014). In the USA, The Centers for Disease Control and 
Prevention (CDC) collect data on antibiotic resistant infections, the cause of the infection and 
factors that may have contributed to the patient acquiring the infection. Informed strategies 
are then developed to prevent the spread of the infection and resistant bacteria (United States, 
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2013).  
 
 
In South Africa, the National Institute for Communicable Disease (NICD) undertakes 
antibiotic resistance surveillance. They have developed a two-tier reporting system. The first 
one is laboratory-based surveillance of antimicrobial resistance (LARS) via the Group for 
Enteric, Respiratory and Meningeal Surveillance in South Africa (GERM SA) (NICD, 2017). 
GERM SA is a nationwide network of microbiology laboratories both in the public and 
private sector that participates in laboratory based surveillance of pathogens of public health 
importance (NICD, 2017). The second reporting system involves electronic surveillance from 
the Corporate Data Warehouse (CDW). CDW is where data is stored from laboratories 
serving all public health sector hospitals in South Africa. Surveillance reports are then made 
available on the NICD website. An example of the latest surveillance reported is the 
Antimicrobial Resistance Surveillance from Sentinel Public Hospitals, South Africa, 2015. 
The objective of the surveillance programme was to record the number of isolates of selected 
pathogens on a monthly basis from selected hospitals. Antimicrobial susceptibility to the most 
important treatment regimens recorded by pathogen and hospital was established. Sixteen 
hospitals from across the country participated in the study. Isolate data of bloodstream 
infections for the period January 2015 to December 2015 was extracted for: Acinetobacter 
baumannii complex, Enterobacter cloacae complex, Escherichia coli, Enterococcus faecalis, 
Enterococcus faecium, Klebsiella pneumoniae, Pseudomonas aeruginosa and Staphylococcus 
aureus (Perovic &Chetty, 2015). Antibiotic susceptibility data was analysed by the CDW. 
Results of each bacterial species included the total number of isolates, their susceptibility 
profiles and percentage susceptibility to selected antibiotics. It is important to monitor trends 
in antibiotic use and resistance in order for evidence-based decisions to be made. It provides 
information for policy makers and heads of departments involved to make informed decisions 
regarding future antibiotic guidelines and recommendations. 
 
1. 2. 6 Antibiotic stewardship 
 
Coupled with surveillance is the need for antibiotic stewardship programmes to optimise 
antimicrobial use. Antibiotic stewardship involves evidence-based interventions to work 
towards improving the appropriate use of antibiotics, assist in containing antimicrobial 
resistance and work on reducing the spread of multi drug resistant organisms (APIC, 2017).  
Antibiotic stewardship involves a range of clinical interventions to try and reduce the 
unnecessary use of antimicrobial agents. The goal of stewardship programmes is to assist in 
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reducing the emergence of antimicrobial resistance caused by selective pressure and to 
optimize patient safety (Pulcini et al., 2017). In 2015, “A Pocket Guide to Antibiotic 
Prescribing for Adults in South Africa” was published on behalf of the South African 
Antibiotic Stewardship Programme (SAASP). A guideline to effective antibiotic stewardship 
is provided in the manual. Firstly it is important to ascertain whether prescribing of an 
antibiotic is required. This is to look for evidence of a bacterial infection. This includes 
checking whether the patient has a fever, inflamed skin, tachypnoea, dysuria as well as any 
raised inflammatory markers (e.g. C Reactive Protein, erythrocyte sedimentation rate). If a 
bacterial infection is suspected then only is the patient started on antibiotics. Cultures must be 
performed before the antibiotic is administered. This allows for de-escalation to a narrow 
spectrum antibiotic once antibiotic susceptibility results are made available. If there is a clear 
site of infection then a specimen from the site of infection must be taken and sent to the 
laboratory for culture testing. If the site of infection cannot be established then a blood culture 
is performed. When choosing empiric treatment it is important to target the most likely 
pathogen of the infection. For example, if a urinary tract infection is suspected it is likely that 
it is gram-negative bacilli causing the infection. The antibiotic of choice is then the narrowest 
spectrum antibiotic implicated in treating a gram-negative bacilli infection. Stewardship 
includes assessing antibiotic resistance. The pharmacist needs to check if there is known 
colonization with resistant pathogen, Health Care Associated Infection (HCAI) or the patient 
has had a course of antibiotics recently. The pharmacist must ensure that there is no 
likelihood of contra indications or drug-drug interactions. Mono-therapy is favoured unless 
there is no alternate to combination therapy or if combination therapy produces a favourable 
synergistic outcome. Pharmacists should also ensure the correct dose and suitable route of 
administration is being used. Pharmacists should encourage physicians to switch from 
intravenous to oral antibiotics whenever possible. When dealing with severe infections the 
appropriate antibiotic treatment must be commenced as soon as possible within the first hour 
of the antibiotic being prescribed to the reduce mortality rate. Antibiotic therapy must be 
monitored on a daily basis (Wasserman et. al, 2015).    Stewardship can be implemented in 
healthcare facilities by creating antimicrobial prescription charts and enforcing appropriate 
prescribing in accordance to the Essential Medicines List (EML) and Standard Treatment 
Guidelines (STGs) (National Department of Health, 2014). Vigilant monitoring should lead to 
a decrease in antibiotic consumption and optimising the use thereof (Messina et. al, 2017). A 
pharmacist-driven study was conducted in 47 private hospitals in South Africa. The study 
assessed the impact of antibiotic stewardship on improving antibiotic use. The study was 
made up of three phases: pre-implementation, implementation and post-implementation. It 
was over five year conducted between October 2009 and September 2014. The primary goal 
was to attain a 10% reduction in antibiotic use and to launch antibiotic stewardship 
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programmes in the facilities that did not have any. The stewardship programme monitored 
five key “process measures”: 
1. Recording the number of cases where antibiotic treatment was commenced before 
cultures had been done. 
2. Recording cases where an antibiotic was used for more than seven days. 
3. Recording cases where antibiotic treatment was given for more than fourteen days. 
4. Recording cases where more than four antibiotics were used concurrently for 
treatment. 
5. Redundant antibiotic treatment – where more than one antibiotic was used with the 
same spectrum of activity (Brink et. al, 2016).  
 
During the pre-implementation phase it was found that 41 out of the 47 hospitals did not have 
an antibiotic stewardship programme in place. Healthcare professionals received training on 
the five targeted process measures. Furthermore, none of the hospitals had local antibiotic 
guidelines or policies. The implementation phase was conducted between February 2011 and 
January 2013. Antibiotic consumption was measured and recorded as DDD per 100 patient 
days. Pharmacists initiated and carried out necessary interventions. Pharmacists also provided 
monthly reports based on the outcomes of the five process measures. Statistics reflected that 
nearly 1 in 15 prescriptions required an intervention to be carried out – in all cases the 
prescriber was consulted first. 39% of these interventions were related to prolonged duration 
of antibiotic treatment (Brink et. al, 2016).  
A similar study was conducted in the public sector to evaluate the outcomes from the Groote 
Schuur Hospital Antibiotic Stewardship Programme initiative. The objective of the study was 
to report antibiotic consumption and implicated costs over a four-year period based on 
information retrieved from the hospital’s antibiotic stewardship programme. The hospital has 
a dedicated antibiotic prescription chart and weekly ward rounds dedicated to antibiotic 
stewardship. Outcomes measured included changes in antibiotic consumption and costs 
involved. The trends in the request of laboratory cultures, in patient mortality and re-
admission rates were also measured. Antibiotic use data during the intervention period 
(01/01/2012 – 31/12/2015) was compared to a control period (01/01/2011 – 31/12/2011). In 
2011 antibiotic consumption was 1046 DDD per 1000 patient days. In 2012 there was no 
change recorded, however, in the subsequent years (2013 – 2015) there was an overall 18% 
decrease in antibiotic consumption. Reduction was noticed most in intravenous antibiotics. 
The inflation – adjusted cost of antibiotics for 2011 was R 2 191 594. This amount decreased 
for every subsequent year during the study period. A sum of R 3 326 340 was saved over the 
four years. In terms of request for laboratory tests – during the study the number of requests 
for full blood count (FBCs) and blood cultures increased from 162 to 2014 and 24.7 to 30.9 
 
  
14 
per 1000 patient bed days. Study outcomes revealed that antibiotic stewardship programmes 
could be introduced into the public sector and could improve antibiotic consumption (Boyles 
et. al, 2017).  
1.2.7 Defined Daily Dose 
 
Medicine utilization studies date back to the 1960s. During those years the importance of 
comparing medicine use between regions and countries was brought to public attention. Work 
done by Arthur Engel and Pieter Siderius (1960) in the medicine utilization field reflected 
differences in the sale of antibiotics in six European countries between 1966 and 1967. This 
led to the first meeting on medicine utilization held by the WHO and saw the development of 
the WHO European Drug Utilization Research Group (DURG) (Kumar et. al., 2013). The 
goal of medicine utilization studies is to assess whether the medicine therapy in question is 
rational or not. For comparative purposes medicine audits should be conducted using the unit 
of measurement developed by researchers in Northern Ireland, Norway and Sweden known as 
defined daily dose (DDD) (WHO, 2003).  Defined Daily Doses (DDD) is a statistical 
measure, and is defined by the WHO as “the assumed average maintenance dose per day for a 
drug used for its main indication in adults” (WHOCC, 2016). In other words, DDD is a 
measure of the amount of medicine that an adult will receive each day for the treatment of an 
implicated infection. DDD is not to be confused with the therapeutic dose for the medication 
(University of Dundee, 2017). Therapeutic dose is the amount of medication required to 
produce a desired effect in terms of treatment (Trevor et. al, 2013). This standardised unit 
allows for trends and comparisons of medicine consumption to be made at an international 
level (WHO, 2017). Medicine consumption is expressed as a rate and therefore it must 
include a denominator and time unit. For outpatient-data DDD per 1 000 inhabitant days is 
used and for in-patient hospital data DDD per 100 bed days is used. DDDs are assigned for 
most medicines with a few exceptions such as topical products, sera, vaccines, antineoplastic 
agents, allergan extracts, contrast media, local and general anaesthetics (WHOCC, 2016). 
Like with any method DDD comes with both advantages and disadvantages. It is 
advantageous in that it is published by the WHO and internationally recognised. DDDs are 
not often changed and therefore this allows for assessments of antibiotic use to be made over 
time. The measurement provides the ability to make comparisons with regards to antibiotic 
use in a standardised way. DDD may not however be a true reflection for a particular 
infection and no DDDs have been established yet for paediatric dosing. There can also be an 
underestimation of antibiotic use due to the fact that alterations to dosing regimens is not 
taken into account (University of Dundee, 2017).  
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In South Africa, the use of DDD as a unit of measure for medicine consumption dates back to 
1996. A preliminary study was carried out in South Africa to evaluate the use of DDD as a 
measure of medicine consumption. The study was conducted in Port Elizabeth. DDD per 
1000 registered patients per day and the cost per DDD was calculated. The study focused on 
antipsychotic, antidepressant, hypnotic and anxiolytic medication. Researchers concluded that 
the DDD was a useful methodology to measure medicine consumption irrespective of what 
type of medicine class was under investigation. DDD is essential in making national and 
international comparisons (Truter et. al, 1996). It is also seen as a useful technique to promote 
rational and cost-effective use of medicines in South Africa. 
 
1.2.8 The use of the DDD methodology to study antibiotic resistance 
 
A study was conducted to evaluate the effects of macrolide use on erythromycin resistance in 
Streptococcus pyogenes (S. pyogenes). This study was conducted in Finland with 
consumption and resistance data for the years 1997 – 2001. During 1997 – 2001 annual 
resistance rates varied from 1.2% to 39%. Annual macrolide and azithromycin use for the 
years 1995 – 2000 varied from 1.15 to 2.85 DDD per 1000 inhabitant days respectively. 
Statistically analysed results reflected a significant association between regional erythromycin 
resistant S. pyogenes and use of macrolides. No significant association was found between 
erythromycin resistance S. pyogenes and azithromycin use. Researchers suggested that this 
could be due to the fact that selection pressure in azithromycin is not as strong as that of other 
macrolides used in the treatment of S. pyogenes. When taking into consideration a lag period 
– the higher the previous antibiotic consumption was, the higher the level of resistance 
witnessed. The relationship between use and resistance is a complex one (Bergman et al., 
2004). Exploring trends in use and resistance gives us some understanding on the topic and 
significant conclusions can be proposed  
 
During 2000 – 2010 there was an outbreak of carbapenem resistant OXA- 48 producing K. 
pneumoniae in a renal unit of a hospital in London, United Kingdom. This led to researchers 
conducting a study of the use of meropenem in this facility. Meropenem consumption data for 
the years 2005-2014 were interpreted as predictors of the OXA-48 producing K. pneumoniae. 
Consumption data was represented as DDD per 100 occupied bed days (OBD). Data was 
captured for 4 years prior and 5 years after the intervention to contain the outbreak. This 
included restricting carbapenem prescribing. This led to the updating of prescribing policies 
to restrict the use of meropenem only in the presence of aminoglycoside – resistant 
 
  
16 
microorganisms. Results reflected that meropenem consumption was highly correlated with 
the production of OXA-48 organisms. By performing a time series analysis researchers were 
able to predict future potential outbreaks. Taking into consideration a 1 year lag period – 
meropenem consumption was most positively correlated with the incidence of OXA-48-
producing K. pneumoniae. Considering the positive correlation it was important to review the 
impact of an antimicrobial stewardship intervention on meropenem usage. Pre intervention 
meropenem consumption showed a year – on – year increase (6.30 to 25.65 DDD/100 OBD). 
Post intervention meropenem consumption revealed a year – on – year decrease (25.65 to 
10.00 DDD/100 OBD). Researchers concluded reducing meropenem usage reduced the 
selective pressure towards carbapenem resistance. This study advocates monitoring 
antimicrobial use as it assists in forecasting the emergence of outbreaks and consequent 
trends in the prevalence of antimicrobial resistance. It also assists in evaluating the impact of 
interventions by reviewing pre and post intervention results (Gharbi, et al., 2015). 
 
The incidence of healthcare acquired (HCA) MRSA and Vancomycin Resistant Enterococci 
(VRE) was noted to be on the rise in Taiwan. Few studies had investigated the association 
between linezolid, fusidic acid or tigecycline exposure and the prevalence of MRSA and 
VRE. A study was carried out in Taiwan using an 11-year period database (2000 – 2010). The 
aim of the study was to investigate “the correlation between consumption of antibiotics 
including vancomycin, teicoplanin, linezolid, tigecycline, fusidic acid and daptomycin and the 
incidence of HCAI-MRSA and HCAI-VRE. Annual consumption data of vancomycin, 
teicoplanin, linezolid, fusidic acid, tigecycline and daptomycin were retrieved from the 
pharmacy database and presented as DDD/ 1000 patient-days. There was no significant 
correlation between the increased use of vancomycin, teicoplanin, tigecycline, fusidic acid 
and the prevalence of HCAI-MRSA. A positive correlation was noted between teicoplanin 
use and HCAI-VRE as well as tigecycline use and HCAI-VRE. Over the study period the use 
of teicoplanin and linezolid had increased significantly whilst the use of the other agents 
remained relatively stable. Researchers speculated that prescribers favoured the use of 
teicoplanin or linezolid over vancomycin when treating MRSA, as they have fewer side 
effects. Such studies allow us to explore correlations between antimicrobial use and 
resistance. Where no significant correlations are found it helps us to understand that we 
should not rely solely on correlations as a method of quantification of use and resistance (Lai 
et. al., 2015).  
 
The use of carbapenems and its correlation with the prevalence of A.  baumanni was surveyed 
in a hospital in Turkey. The study was conducted from 1 May 2011 to 28 February 2013. The 
study consisted of 2 study observations: carbapenem non – restricted period and a 
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carbapenem-restricted period. During the restriction period the use of carbapenems was 
restricted to patients where alternate therapy was not possible. Carbapenem consumption and 
the number of patients with multi drug resistant (MDR) A.  baumanni were evaluated. A total 
of 10.82 DDD/ 100 ICU bed days of carbapenem was used when no restrictions were in 
place. During the carbapenem restriction period this rate dropped to 6.95 DDD/ 100 ICU bed 
days. During the carbapenem non-restrictive phase, 3.98% MDR A. baumanni were detected 
whereas this figure dropped to 1.82% when restrictions on carbapenem use were enforced. 
Results show that there was a 2.24 fold higher prevalence of MDR A.  baumanni in a non-
controlled environment. This study showed that antibiotic restriction results in a decline in 
resistance. Researchers were able to achieve a 2-fold reduction the outbreak of a life 
threatening infection (Ogutlu, 2014).   
 
A study was conducted over a 5-year period (1 January 2000 to 31 December 2004) to 
measure antibiotic use and antibiotic resistance patterns in an intensive care burn department 
in a hospital in Tunisia. The increasing use of antibiotics in hospitals and the subsequent 
economic implications led researchers to investigate antibiotic use in this hospital. 
Antimicrobial density (antibiotic in grams converted to DDD and number of hospitalization 
days) was calculated for imipenem, ceftazidime, ofloxacin, ciprofloxacin and piperacillin-
tazobactam. Results reflected a relationship between ceftazidime use and ceftazidime resistant 
K.  pneumoniae. There was no significant relationship between the use of ceftazidime and 
resistance to P.  aeruginosa but a relationship was witnessed with the consumption of 
ciprofloxacin and the rate of ciprofloxacin resistant P. aeruginosa. It was concluded that 
monitoring antibiotic consumption and correlating it with resistance is a necessity in order to 
implement policies to reduce the existing global antimicrobial resistance burden (Messadi et. 
al, 2008). Monitoring of use correlated with resistance allows us to assess where problem 
areas lie and where resources need to be used to try and resolve these problems. 
 
It was only as late as 2005 that the first study on the relationship between antibiotic 
consumption and antibiotic use was carried out in the Lagos University Teaching Hospital in 
Nigeria. Prior to the study there had been no real attempts to investigate the appropriateness 
of antibiotic use in Nigerian hospitals, hence the need for the study. The study was conducted 
between January 2005 and June 2006, to improve researchers’ knowledge on the relationship 
between antibiotic consumption rates and antibiotic resistance rates of uro-pathogens. Nigeria 
reported inappropriate prescribing of antibiotics by medical practitioners and the abuse of 
antibiotics by patients. The names of antibiotics usually used to treat urinary tract infections 
(UTIs) and corresponding number of grams per unit per package were entered into a spread 
sheet. Thereafter the number of packages of each antibiotic consumed between January 2005 
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and June 2005, and July 2005 and December 2005, and January 2006 and June 2006 was 
recorded. DDD for each antibiotic for the 6-monthly periods was generated and a 6-monthly 
comparison of antibiotic resistance and consumption rates were analysed using Pearson’s 
correlation coefficient. The antibiotics most commonly prescribed during the study period 
were ciprofloxacin and amoxicillin-clavulanic acid whilst trimethoprim-sulphamethoxazole 
was the least prescribed. Interestingly, resistance rates were highest for trimethoprim-
sulphamethoxazole followed by amoxicillin-clavulanic acid (Oduyebo et. al, 2008). Selection 
pressure from the use of one antibiotic class may co-select resistance to other antibiotic 
classes as resistance genes are frequently co-carried on mobile genetic elements (Essack, et. 
al, 2005). A fairly short study period was used however significant trends and correlation 
between resistance and consumption were identified (Oduyebo et. al, 2008). 
 
From the international and local literature reviewed for the purposes for this study. It is 
evident that antimicrobial surveillance studies in Africa are still in the inception phase. 
Evidence based studies are required for effective policy interventions to take place (Osman et. 
al., 2016).  As presented in the literature above, the importance of surveillance, research and 
optimizing the use of antibiotics has been recognised both internationally (WHO GAP) and 
locally (SA AMR Framework). Optimizing antibiotic use by antibiotic stewardship 
programmes have proven successful in studies conducted in South Africa’s private and public 
sectors. Co-ordinated efforts are required to update knowledge through research and 
surveillance, strictly enforce existing policies and address indiscriminate antibiotic use. A 
study of this nature has not been conducted in the proposed district (uMgungundlovu district). 
Data obtained from this study may be used to compare and contrast antibiotic consumption 
and resistance patterns at other South African public healthcare facilities.  This study is a 
preliminary step in evaluating the current antibiotic use and associated resistance burden on a 
district level. DDD’s, as a standard unit of measurement, has proven effective in all the 
studies reviewed. The literature presented serves as a motivation to explore trends in 
antibiotic use and resistance patterns. DDD is approved and widely used as a unit of measure 
for representing antimicrobial consumption. Studies cited have successfully explored 
probable trends between antimicrobial use and resistance and have proven effective in 
capturing the epidemiological interpretation of antibiotic consumption on resistance.  
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1.3 AIMS AND OBJECTIVES  
 
This study aimed to quantify and explore trends in antibiotic use and resistance in three public 
hospitals in the uMgungundlovu district at different levels of healthcare using defined daily 
doses (DDDs)/1000 inhabitants as consumption data and antimicrobial susceptibility data 
from existing databases. 
 
The study had the following objectives: 
 
1. To calculate DDDs (as a measure of consumption) in a tertiary, regional and district, 
hospital in uMgungundlovu using depot-issuing data. 
2. To compare and contrast antibiotic consumption at the different levels of healthcare 
in the district. 
3. To compare and contrast antibiotic susceptibility at the different levels of healthcare 
in the district.  
4. To demonstrate, whether there are any significant associations between antibiotic 
consumption (presented as DDD) and resistance from microbiology data obtained 
from the hospitals. 
 
1.4 OVERVIEW OF STUDY DESIGN AND METHODOLOGY AND  
 
Ethical Considerations 
 
A request was made to the Head of the Department of Health (DoH) of KwaZulu-Natal, the 
Head of Pharmaceutical Service of Kwa Zulu Natal and the District Health Manager of the 
uMgungundlovu district to conduct the study in the uMgungundlovu district. The University 
of KwaZulu-Natal’s Human and Social Sciences Research Ethics Committee granted ethical 
approval to conduct the study. Upon successful consent from all parties involved the Head of 
the Provincial Medical Supply Centre provided depot-issuing data that delineated the 
medicines and their quantities issued to the hospitals by central stores. The National Institute 
for Communicable Diseases (NICD) provided the necessary microbiology information, i.e. 
antimicrobial susceptibilities of Escherichia coli and Staphylococcus aureus as representative 
Gram-negative and Gram-positive bacteria respectively from the hospitals in question for the 
period 2014-2017.  
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Study Site 
 
Study data was from three hospitals in the uMgungundlovu District. These hospitals were 
selected in order for comparisons to be made at different levels of healthcare (district, 
regional and tertiary hospitals). The district provides a health service to 10% of the KwaZulu-
Natal province which is an estimated 1 052 730 individuals. uMgungundlovu district has also 
been selected as a pilot district for National Health Insurance (NHI) to be implemented in 
South Africa (DoH, 2016). 
 
Study design 
 
The study sought to investigate trends between antibiotic consumption and resistance at 
different levels of healthcare. An observational, retrospective study was undertaken. 
Aggregated data was used. Provincial depot issuing data which lists the medicines and the 
quantities issued to the hospitals by central stores was used to calculate the DDDs. Antibiotic 
susceptibility data that was required for the hospitals was obtained from the NICD.  
 
Antibiotic Use 
 
Consumption data received from the DoH for the years 2014 to 2016 was filtered to find the 
data required for the antibiotics in question. This data was used to calculate DDD using the 
WHO/ATC DDD consumption tool. Step-by-step Guidelines provided by WHO 
Collaborating Centre for Drug Statistics Methodology on their website was used to accurately 
capture data on the electronic Antimicrobial Consumption (AMC) Tool which automatically 
calculated DDD once data was successfully entered. The pathogens under investigation were 
E. coli (Gram-negative bacteria) and S. aureus (Gram-positive bacteria). The antibiotics that 
were selected to calculate DDD were therefore based on their indication for infections caused 
by the bacteria mentioned. The antibiotic panel for E. coli was constituted by amoxicillin-
clavulanic acid, ampicillin, amikacin cefepime, cefotaxime, ceftazidime, ceftriaxone, 
ciprofloxacin, colistin, gentamicin, imipenem, levofloxacin, meropenem, piperacillin-
tazobactam, trimethoprim-sulphamethoxazole. The antibiotic panel for S. aureus was 
constituted by azithromycin, cefoxitin, cloxacillin, clindamycin, linezolid and vancomycin. 
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Antibiotic Resistance 
 
Susceptibility data for E .coli and S. aureus was obtained from the NICD for the years 
2014 – 2017 in the resistant, intermediate, susceptible  (R, I, S) format. E. coli and S. 
aureus were categorised as susceptible or non-susceptible to the panel of antibiotics 
indicated for treatment of infections caused by the organisms.  
 
Statistical Analysis 
 
Categorical data were reported as percentage specimens stratified by level of hospital care 
(tertiary, regional, district).  An overall chi square test was used to compare percentages of 
isolates susceptibility by hospital level for each antibiotic.  If the overall chi-square was 
significant (p < 0.05), pairwise comparisons were explored.  Where more than one 
comparison was significant, the most conservative p-value was reported 
 
Kruskal-Wallis analysis of variance was used to compare average DDD per 1000 inhabitants 
by hospital level for each antibiotic.  Overall significance was reported where the differences 
were not significant.  Where significant, the overall p-value was not reported. Instead the 
Duncan multiple range test was used to test pairwise comparisons.  Where multiple pairwise 
comparisons were significant, the most conservative p value was reported 
 
Data was analysed using Stata v13 statistical software. 
 
1.5 CHAPTER STRUCTURE 
 
This research is presented in the following chapters: 
 Chapter 1. The first chapter contains the introduction, literature review and a brief 
overview of the study design and methodology. 
 Chapter 2. The second chapter consists of the manuscript entitled “Exploring trends 
between antibiotic use and resistance in public hospitals in the uMgungundlovu District” 
intended for publication in the South African Medical Journal. 
 Chapter 3. The final chapter reflects on the extent to which the aim and objectives have 
been met, limitations are identified, recommendations are made and the significance of 
the study is presented. 
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Abstract 
Background: Surveillance of antibiotic use and resistance plays an important role in 
identifying the drivers of antibiotic resistance.   This study sought to identify trends and 
possible correlations between antibiotic use and resistance in three public sector 
hospitals at different levels of healthcare. Antibiotic use data was represented as defined 
daily doses (DDD)/1000 inhabitants and thereafter correlated with susceptibility data 
of antibiotics indicated for the treatment of Escherichia coli and Staphylococcus aureus 
as indicator Gram-negative and Gram-positive bacteria respectively. 
Methods This was a retrospective, observational study conducted at three public 
healthcare facilities in the uMgungundlovu district. Data was obtained and analysed 
for the period 2014-2016. Provincial depot issuing data was used to calculate 
antibiotic consumption as defined daily doses/1000 inhabitants for each antibiotic, 
using World Health Organization (WHO) methodology. Antibiotic susceptibility data 
was obtained from the National Institute for Communicable Diseases (NICD) and was 
analysed based on susceptible and non-susceptible isolates for each antibiotic under 
investigation. Data was analysed using Stata v13 statistical software 
Results There was a general trend of reduced antibiotic susceptibility as the levels of 
healthcare increased attributed to the fact that more severe and complex infections are 
treated at the higher levels of healthcare and require greater quantities of and/or 
broader spectrum antibiotics. For treatment of infections caused by S. aureus 
antibiotic use generally increased as the level of healthcare increased. Azithromycin 
was the most frequently used while  linezolid was the least used antibiotic and 
showed the highest levels of susceptibility across all levels of healthcare. S. aureus 
showed the lowest level of susceptibility to cloxacillin across all the levels of 
healthcare and was indicative of the prevalence of methicillin-resistant S. aureus 
(MRSA). When antibiotic use was correlated with resistance, cloxacillin displayed a 
downward trend in use from 2014 to 2016 while cloxacillin resistance increased from 
2014 to 2015 followed by a decrease in resistance in 2016 indicating that resistance is 
a function of time and use and that the lag time between the decrease in use and a 
corresponding decrease in resistance is not predictable and varies for different 
antibiotics in different healthcare settings. In contrast, azithromycin showed a steady 
decline in resistance although use increased over the three years (2014-2016).  In the 
case of the treatment of infections caused by E. coli there was a general trend of the 
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greater use of narrow spectrum antibiotics at the lower district and regional levels 
while the  broad-spectrum antibiotics were used more frequently at a tertiary level. 
Trimethoprim-sulphamethoxazole was used the most, whereas colistin was used the 
least. Contrary to expectations, there were higher susceptibility levels to third and 
fourth generation cephalosporins and meropenem at a tertiary level than regional 
level. E. coli showed lowest levels of susceptibility to ampicillin and highest level of 
susceptibility to levofloxacin across all levels of healthcare.  When antibiotic use was 
correlated with resistance, antibiotics that were used frequently (sulphamethoxazole-
trimethoprim, amoxicillin clavulanic acid and ampicillin) displayed high levels of 
resistance over the three years. Trimethoprim-sulphamethoxazole use decreased 
slightly over the year however resistance remained high. The same trend was 
observed with amoxicillin clavulanic acid and ampicillin use and resistance indicating 
possible co-selection of resistance by the use of other classes of antibiotics.  
Conclusion This study added to the body of knowledge that there exists a link 
between the use of antibiotics and resistance, albeit not a direct causal one. 
Quantifying antibiotic use and identifying trends in resistance associated with 
antibiotic consumption assists prescribers and policy makers to improve antibiotic 
use, guide antibiotic stewardship programmes and optimise antibiotic policies and 
guidelines. 
 
Keywords: Escherichia coli; Staphylococcus aureus; Defined Daily Doses; Antibiotic 
Consumption; Antibiotic Susceptibility; Antibiotic Resistance; Antibiotic Stewardship 
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Introduction 
 
The advent of antibiotics in the 1920’s has been pivotal in the treatment of bacterial 
infections. However, the indiscriminate use of antibiotics over the years has exerted 
selection pressure for the emergence of resistance that has reached unprecedented 
levels globally [1].  Two strategic objectives of the Global Action Plan (GAP) on 
Antimicrobial Resistance are (1) the surveillance of antibiotic use and resistance in 
order to identify the drivers of resistance and (2) evidence-based prescribing and 
dispensing to optimize antimicrobial use [2]. The vision of the South African 
Antimicrobial Resistance National Strategic Framework, 2014 – 2024 is “to ensure 
the appropriate use of antimicrobials by health care professionals in all health 
establishments in South Africa to conserve the efficacy of antimicrobials for the 
optimal management of infections and animal health” [3]. The framework draws 
attention to three main areas that contribute to improving the rational use of 
antibiotics and improving patient outcomes: (1) enhance infection prevention and 
control through vaccination programmes and improving water access and sanitation, 
(2) antibiotic stewardship interventions such as multi-disciplinary ward rounds and 
antibiotic prescription charts aimed at reducing unnecessary prescribing of antibiotics, 
and,  (3) optimization of antibiotic surveillance which entails the monitoring of 
antibiotic use and resistance patterns[3].  
 
Antibiotic use may be quantified as defined daily dose (DDD), which is “the assumed 
average maintenance dose per day for a drug used for its main indication in adults.” It 
is a statistical tool used in medicine utilization research to improve medicine use. 
DDD is a fixed independent unit of measure that allows for the assessment of 
medicine trends and comparisons to be made internationally [4].  Antimicrobial 
consumption data represented as DDD can then be correlated with antibiotic 
susceptibility data to ascertain the drivers and trends in antibiotic use and resistance.  
This study explored the trends between antibiotics indicated for the treatment of 
Escherichia coli and Staphylococcus aureus in three public sector hospitals at 
different levels of healthcare, i.e. district, regional and tertiary in the uMgungundlovu 
district. Retrospective data on antibiotic use and resistance was analysed for the years 
2014 – 2016/7 with antibiotic use correlated with antibiotic susceptibility for the 
selected isolates.  
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Methods 
 
An observational, retrospective study was undertaken to quantify and analyse the 
relationship between antibiotic use and resistance. Data on antibiotic use and 
resistance was obtained for three hospitals at different levels of care (district, regional 
and tertiary) in the uMgungundlovu District over the study period of 2014-2016. The 
district provides a health service to 10% of the KwaZulu-Natal province which is an 
estimated 1 052 730 individuals [5]. 
 
Antibiotic Consumption data 
 
Annual consumption data received from the Pharmaceutical Services Division of the 
KwaZulu-Natal Provincial Department of Health for the years 2014 to 2016 was 
filtered to find the data required for the antibiotics in question. This data was used to 
calculate DDD using the World Health Organization Collaborating Centre (WHOCC) 
for Drug Statistics Methodology consumption tool. Step-by-step guidelines provided 
by WHOCC on their website were used to accurately capture data on the electronic 
Antimicrobial Consumption (AMC) Tool which automatically calculated DDD once 
data was successfully entered [6]. Briefly, antibiotic consumption data in grams was 
converted into DDD. This is calculated by taking the total number of grams for each 
antibiotic and dividing it by number of grams per daily dose as indicated by WHO 
guidelines. DDD was adjusted to DDD per 1000 inhabitant days by taking DDD 
divided by total number of inhabitant multiplied by 365 days and then multiplying by 
1000 [6].  The population denominator was chosen as (1) these three hospital form part 
of the referral system serving the total population of the uMgungundlovu district, (2) 
all three hospitals have a substantive out-patient population in addition to in-patients 
and (3) the susceptibility data was not stratified by out-patient and in-patient. (The 
potential limitations of this denominator choice are elaborated in the Discussion). The 
pathogens under investigation were E. coli (Gram-negative bacteria) and S. aureus 
(Gram-positive bacteria). The antibiotics that were selected to calculate DDD were 
therefore based on their indications for infections caused by the bacteria in question as 
recommended by the South African Antibiotic Stewardship Programme (SAASP) [7]. 
The antibiotic panel for E. coli was amikacin, amoxicillin/clavulanic acid, ampicillin, 
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cefepime, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, colistin, gentamicin, 
imipenem, levofloxacin, meropenem, piperacillin/tazobactam, and trimethoprim 
sulphamethoxazole. The antibiotics selected for S. aureus were azithromycin, 
cloxacillin, clindamycin, linezolid and vancomycin. 
 
Antibiotic Resistance 
 
Susceptibility data for E. coli and S. aureus was obtained from the National Infectious 
Diseases Centre (NICD) for the years 2014 – 2017. E. coli and S. aureus were 
categorised as susceptible or non-susceptible to the panel of antibiotics in the 
resistant, intermediate, susceptible (R, I, S) format. . Percentage susceptibility was 
calculated.  
 
Statistical Analysis 
 
Categorical data were reported as per cent of specimens examined by hospital level of 
care (tertiary, regional, district).  An overall chi square test was used to compare 
percentages of isolates susceptibility by hospital level for each antibiotic.  If the 
overall chi-square was significant (p < 0.05), pairwise comparisons were explored.  
Where more than one comparison was significant, the most conservative p-value was 
reported 
 
Kruskal-Wallis analysis of variance was used to compare average DDD per 1000 
inhabitants by hospital level for each antibiotic.  Overall significance was reported 
where the differences were not significant.  Where significant, the overall p-value was 
not reported. Instead the Duncan multiple range test was used to test pairwise 
comparisons.  Where multiple pairwise comparisons were significant, the most 
conservative p value was reported 
 
Data was analysed using Stata v13 statistical software. 
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Results 
 
Table I shows antibiotic consumption for the antibiotics selected based on their 
indication for infections caused by S. aureus presented as the mean DDD per 1000 
inhabitants for the different levels of hospital-based health care (2014-2016). 
 
Table I. Antibiotic consumption based on their indication for infections caused by S. 
aureus presented as the mean DDD per 1000 inhabitants for the different levels of hospital-
based health care (2014-2016) 
 Hospital level 
 District  Regional  Tertiary   Pairwise Comparison‡ 
 
Antibiotic Mean*  Mean * Mean* p-
value† 
District 
vs. 
Regional 
District 
vs. 
Tertiary 
Regional 
vs. 
Tertiary 
Azithromycin 0.058 0.110 0.015 0.03 0.09 0.09 0.004 
Clindamycin 0.000 0.006 0.011 0.04 0.07 0.006 0.1 
Cloxacillin 0.010 0.032 0.019 0.1 - - - 
Linezolid 0.000 0.001 0.000 0.07 - - - 
Vancomycin 0.000 0.002 0.008 0.03 0.09 0.004 0.09 
* DDD per 1 000 inhabitants 
† Chi-square test 
‡ If p-value was <0.05 a pairwise comparison made between two of the participating hospitals at 
different levels of healthcare  
 
Azithromycin, clindamycin and vancomycin were the three antibiotics to which a 
statistically significant (p<0, 05) difference in use was observed between the different 
levels of care. Pairwise comparison revealed a statistically significant difference in 
azithromycin use between regional and tertiary hospitals where use was greater at 
regional level. Pairwise comparisons also showed statistically significant differences 
in clindamycin and vancomycin use between district and tertiary levels with greater 
use at tertiary level.  Azithromycin was most frequently used. Vancomycin was not 
used at district level and its use at regional and tertiary level for the 3 years was 
minimal.  
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There were a total of 121 525 isolates from the three participating hospitals over the 
period 2014-16, amongst which were 24 579 S. aureus isolates and 96 946 E. coli 
isolates.   
 
Table II shows antibiotic susceptibility (%) for each antibiotic based on their 
indication for infections caused by S. aureus for different levels of hospital-based 
health care (2014-2016) 
 
Table II. Antibiotic susceptibility (%) for each antibiotic based on their indication for 
infections caused by S. aureus for the different levels of hospital-based health care (2014-2016) 
 Hospital level 
 District  Regional Tertiary   Pairwise 
 
Antibiotic % % % p-
value† 
District 
vs. 
Regional 
District 
vs. 
Tertiary 
Regional 
vs. 
Tertiary 
Azithromycin 87.9 88.2 80.8 <0.001 0.9 0.007 <0.001 
Clindamycin 90.1 87.9 79.1 <0.001 0.3 <0.001 <0.001 
Cloxacillin 88.8 88.0 77.8 <0.001 0.7 <0.001 <0.001 
Linezolid 100 100 100 - - - - 
Vancomycin 100 99.9 99.8 0.5 - - - 
 
A general trend of decreased susceptibility with higher levels of healthcare was 
observed.  The susceptibility of S. aureus to azithromycin susceptibility was 
significantly lower at tertiary level than at district and regional levels and showed the 
lowest susceptibility compared to other antibiotics.  Clindamycin susceptibility 
decreased as the level of care increased.  Cloxacillin resistance ranged between 11, 
2% to 22, 2% indicative of 11, 2% and 22, 2% methicillin-resistant S. aureus (MRSA) 
at district and tertiary levels respectively. Vancomycin-resistant S. aureus (VRSA) 
appeared to be emerging at regional and tertiary levels but linezolid retained full 
(100%) susceptibility at all levels. 
 
Table III shows antibiotic consumption for the antibiotics selected based on their 
indication for infections caused by E. coli presented as mean DDD per 1000 
inhabitants for different levels of hospital-based health care (2014 – 2016).  
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Table III. Antibiotic consumption based on their indication for infections caused by E. coli 
presented as mean DDD per 1000 inhabitants for different levels of hospital-based health care 
(2014 – 2016) 
 Hospital level 
 District  Regional  Tertiary   Pairwise 
Antibiotic Mean*  Mean * Mean* p-
value† 
District 
vs. 
Regional 
District 
vs. 
Tertiary 
Regional vs. 
Tertiary 
Amikacin 0.000009 0.0009 0.005 0.051 - - - 
Amoxicillin/ 
clavulanic acid 
0.020 0.078 0.036 0.04 0.01 0.1 0.07 
Ampicillin 0.013 0.047 0.015 0.07 - - - 
Cefepime 0.00005 0.0001 0.0002 0.04 0.06 0.01 0.1 
Cefotaxime 0.00002 0.001 0.000 0.03 0.004 0.09 0.09 
Ceftazidime 0 0.0002 0.001 0.03 0.09 0.003 0.09 
Ceftriaxone 0.020 0.047 0.009 0.03 0.09 0.09 0.004 
Ciprofloxacin 0.041 0.067 0.056 0.4 - - - 
Colistin 0 0.0002 0.0001 0.06 - - - 
Gentamicin 0.0035 0.020 0.013 0.051 - - - 
Imipenem 0 0.012 0.024 0.051 - - - 
Levofloxacin 0 0.0005 0.0010 0.04 0.06 0.005 0.1 
Meropenem 0 0.002 0.003 0.04 0.06 0.005 0.1 
Piperacillin/ 
Tazobactam 
0.00001 0.018 0.018 0.07 - - - 
Trimethoprim 
sulphamethoxazo
le 
0.443 1.009 0.341 0.2 - - - 
* DDD per 1 000 inhabitants 
† Chi-square test 
 
There was a general trend of greater use of narrower spectrum antibiotics at regional 
level (e.g. ampicillin, amoxicillin-clavulanic acid and trimethoprim-
sulphamethoxazole) while broader spectrum antibiotics were more frequently used at 
the higher tertiary level of care (e.g. amikacin, ceftazidime, cefepime, imipenem, 
meropenem and levofloxacin).  Statistically significant differences in use were 
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evident for amoxicillin/clavulanic acid, all third and fourth generation cephalosporins, 
meropenem and levofloxacin mainly between district and regional and/or tertiary 
levels.  Only ceftriaxone showed a significant difference in use between regional and 
tertiary levels of care. Trimethoprim-sulphamethoxazole was the most frequently used 
antibiotic at all levels of care with no statistical significance across the levels of health 
care followed by amoxicillin/ clavulanic acid and ampicillin.  Carbapenem, colistin 
and piperacillin/tazobactam use was minimal.  
 
Table IV shows antibiotic susceptibility (%) for each antibiotic based on their 
indication for infections caused by E. coli for different levels of hospital-based health 
care (2014-2017). 
Table IV. Antibiotic susceptibility (%) for each antibiotic based on their indication for 
infections caused by S. aureus for different levels of hospital-based health care (2014 – 
2016) 
 Hospital level 
 Distri
ct 
Regional  Tertiary   Pairwise comparison 
 
Antibiotic % % % p-
value† 
District 
vs. 
Regional 
District 
vs. 
Tertiary 
Region
al vs. 
Tertiary 
Amikacin 92.9 95.2 93.9 0.07 - - - 
Amoxicillin 
clavulanic acid 
56.8 60.7 56.3 0.003 0.3 0.9 0.001 
Ampicillin 16.2 16.6 15.8 0.7 - - - 
Cefepime 72.0 78.3 72.6 <0.00
1 
0.046 0.9 <0.001 
Cefotaxime/ 
Ceftriaxone 
70.3 80.0 72.8 <0.00
1 
0.001 0.46 <0.001 
Ceftazidime 72.5 80.7 72.8 <0.00
1 
0.007 0.9 <0.001 
Ciprofloxacin 69.7 78.7 64.6 <0.00
1 
0.004 0.2 <0.001 
Colistin 97.8 99.6 99.5 0.002 - - - 
 
  
41 
 
Statistically significant differences in susceptibility of E. coli to amoxicillin-
clavulanic acid, the third and fourth generation cephalosporins and ciprofloxacin were 
evident between regional and tertiary levels with lower susceptibility in the latter.  A 
similar trend was observed for the third and fourth generation cephalosporins and 
meropenem between district and regional levels of care with lower susceptibility 
observed in the former, contrary to expectations.  This contradiction was also 
observed for meropenem between the district and tertiary levels of care with lower 
susceptibility again at district level.  E. coli showed the lowest level of susceptibility 
to ampicillin,  ranging between 15% -16% across all three hospitals, followed by 
trimethoprim-sulphamethoxazole ranging from 25,2-28% and amoxicillin-clavulanic 
acid ranging from 56,3-60,7%.  Although use of carbapenems, colistin and 
piperacillin/tazobactam was minimal, resistance was present; ranging between 17, 3% 
- 22, 9% across the three hospitals. Piperacillin/ tazobactam susceptibility was 
significantly lower at tertiary level compared to regional level and there was no 
significant difference between district and tertiary levels. 
 
 
 
 
 
  
Gentamicin 78.1 87.9 81.9 <0.00
1 
- - - 
Imipenem 100 99.7 99.5 0.2 - - - 
Levofloxacin 100 - 100 - - - - 
Meropenem 97.8 99.8 99.4 <0.00
1 
<0.001 0.01 0.006 
Piperacillin/ 
Tazobactam 
77.1 82.7 78.3 <0.00
1 
0.057 0.7 <0.001 
Trimethoprim 
Sulphamethoxazole 
28.0 25.2 26.9 0.3 - - - 
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Figure I graphically portrayed the trend between antibiotic consumption and 
resistance for all three hospitals with regards to treatment of infections caused by S. 
aureus. 
 
Figure I showing combined yearly antibiotic consumption and resistance trends 
for all three hospitals implicated in the treatment of S. aureus 
 
Cloxacillin displayed a trend where resistance increased from 2014 to 2015 and when 
antibiotic usage decreased in 2016 so did resistance. There was a decrease in 
resistance to clindamycin over the years. Vancomycin use increased from 2014 to 
2015 and decreased thereafter in 2016 with resistance remaining minimal. 
Azithromycin consumption increased over the three years but there was a steady 
decline in resistance. 
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 Figure II graphically portrayed the trend between antibiotic consumption and resistance for all 
three hospitals with regards to treatment of infections caused by E. coli. 
 
Figure II showing combined yearly antibiotic consumption and resistance trends for all 
three hospitals implicated in the treatment of Escherichia coli 
 
Trimethoprim-sulphamethoxazole and ampicillin consumption decreased over the three 
years but resistance levels remained high. There was a slight decrease in amoxicillin 
resistance in 2016 with a decrease in amoxicillin consumption between 2015 and 2016. 
Although ciprofloxacin usage decreased over the three years there was a steady increase 
in ciprofloxacin resistance. 
Discussion 
 
This study explored the trends in antibiotic use (calculated as DDD/1000 inhabitants) 
and susceptibility patterns in a Gram-negative organism (E. coli) and a Gram-positive 
organism (S. aureus) at different levels of healthcare in a single district in KwaZulu-
Natal, South Africa. Data from all three hospitals were further aggregated and 
correlations between antibiotic use consumption and resistance were explored in an 
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effort to ascertain the impact (if any) of selective pressure on the emergence of 
antibiotic resistance.  
 
Three general trends were evident:  (1) there was greater use of narrower spectrum 
antibiotics at the lower district and regional levels while broader spectrum antibiotics 
were more frequently used at the higher tertiary level of care, (2) decreased antibiotic 
susceptibility was evident at higher levels of healthcare and (3) there was no direct 
causal relationship between antibiotic use and resistance.   
 
General trends (1) and (2) re-iterate the principle behind the healthcare referral system 
of South Africa. Patients are referred to a district hospital if adequate treatment is not 
available from a primary healthcare level. If further complex treatment is required 
patients are to be referred from a district to a regional hospital. If the regional hospital 
does not have the requisite services, then the patient is referred from a regional to a 
tertiary hospital where diagnostic procedures and treatment of a specialized nature is 
provided [8]. Conditions that are more severe that require the use of broad-spectrum 
antibiotics are used at the higher levels of healthcare.  The third trend speaks to the 
co-selection of resistance and the role infection prevention and control. Co-selection 
refers to resistance to more than one antibiotic due to a genetic linkage of the resistant 
genes. The use of one antibiotic could result in resistance to that as well as other 
classes of antibiotics whose resistance genes are co-carried on the same piece of DNA 
usually on mobile genetic elements such as plasmids, transposons and integrons [9]. 
Therefore, a direct relationship between the use of a single antibiotic or antibiotic 
class and the emergence of resistance is difficult to prove. Moreover, a confounding 
factor is the transfer of infections is through contact between within and between 
patients and healthcare workers [10]. There is the increasing need for reinforcing hand 
hygiene and maintaining good hospital cleaning practices, staff education, improved 
communication and antibiotic stewardship interventions to uphold a favourable 
infection control standard within hospitals [11].  
 
When antibiotic consumption and resistance was compared by hospital level it was 
evident that azithromycin was used most frequently and was associated with the 
lowest susceptibility of all the antibiotics tested against S. aureus albeit ranging 
between 80, 8% and 88, 2% (Table I).  The same trend was found with trimethoprim-
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sulphamethoxazole, ampicillin and amoxicillin/clavulanic acid use and resistance. 
This supports the theory that although the relationship between antibiotic use and 
resistance is not a causal one, there is a link between selection pressure of antibiotic 
use and the emergence of resistance [12-14]. Antibiotic use of vancomycin, colistin, 
carbapenems (meropenem and imipenem) and piperacillin/tazobactam displayed 
increase in use as the level of care increased. This is in accordance with the referral 
system where broader spectrum antibiotics are used at higher levels of care in treating 
more complex conditions [14]. The 100% susceptibility of linezolid in all three 
hospitals and vancomycin at the district hospital is welcomed and hopefully will be 
maintained (Table II). It is important to reserve these antibiotics for the treatment of 
severe infections where no alternative treatment is available.  
 
According to SAASP guidelines for methicillin susceptible S. aureus (MSSA) 
cloxacillin, clindamycin, ceftriaxone and amoxicillin clavulanic acid are the 
antibiotics of choice [7]. Resistance to cloxacillin and clindamycin already range 
between 10%-22.2% (Table II). It is important to work on interventions to prevent 
further resistance to these antibiotics.  For MRSA vancomycin is indicated, as the 
antibiotic of choice and clindamycin and moxifloxacin should only be prescribed if 
sensitivity results have been obtained. Bearing this in mind the high susceptibility 
levels of vancomycin need to be retained.  
 
According to SAASP guidelines, the recommended first line treatment of E. coli is 
ceftriaxone, amoxicillin/clavulanic acid, ciprofloxacin and aminoglycosides 
(gentamicin, amikacin etc.). The choice of antibiotic is dependent on the type of 
infection. Ampicillin is not recommended as an antibiotic of choice due to frequent 
resistance and poor clinical outcome and trimethoprim-sulphamethoxazole should 
only be used when sensitivity results have been obtained [7]. The high level of 
resistance to ampicillin and trimethoprim-sulphamethoxazole was evident in our study 
across all levels of care.   It is important to incorporate these guidelines into hospital 
antibiotic policies, standard treatment guidelines and associated national essential 
medicines lists, and to notify prescribers of the recommended first line therapy for 
infections caused by the bacteria in question. This is to assist in reducing the 
indiscriminate use of antibiotics and the subsequent emergence and spread of 
resistance.  
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There is a plethora of studies exploring and examining the link between antibiotic use 
and resistance. The correlation is not a direct one. For example when yearly trends 
between antibiotic consumption and resistance were investigated, ciprofloxacin 
consumption had decreased over the study period however resistance to the antibiotic 
had increased over the years. This could be attributable to confounding factors which 
include and are not limited to infection prevention and control measures, invasive 
procedures in the hospital setting, patient history, disease profile and timely 
administration of antibiotics by nursing staff [15]. Confounding factors were not 
included in this study and proved to be a limitation. Reduction in resistance also 
varies across bacteria. Rate of resistance is associated with the way in which 
resistance is developed either through de novo mutation or acquired resistance 
(Horizontal Gene Transfer (HGT) of resistant determinants) [9]. Therefore trying to 
correlate antibiotic use and resistance on a yearly basis proved to be complex. A 
direct causal relationship between antibiotic use and resistance was not achieved. On-
going surveillance at hospitals need to be established. This will assist in having 
updated hospital records on antibiotic use and resistance within the facility. Data can 
be presented to hospital management, policy makers and prescribers to make them 
aware of the current antibiotic consumption and resistance statistics of the facility. If 
possible, reduction of unnecessary antibiotic prescribing should be achieved without 
compromising patient outcomes.  
 
The main limitation of the study in terms of denominator data was that information on 
patient numbers provided with antibiotics was not available. This is a result of sub-
optimal information systems in the public sector. Moreover, patient record databases 
in the public sector are not electronically captured necessitating the use of catchment 
population data as the denominator (DDD/1 000 inhabitants). The use of DDD/1 000 
inhabitants allows one to assume in and out patient consumption, however, this may 
be an underestimation of use. Bed occupancy (DDD/100 bed days) is an estimate of 
inpatient consumption only and could therefore result in overestimation.  
 
Selective pressure is a concern when it comes to the emergence of resistance and 
steps should be taken to reduce the indiscriminate use of antibiotics.  
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Conclusion 
 
This study compared antibiotic use and susceptibility at three levels of hospital care. 
In most cases, a trend of highest antibiotic susceptibility was found on a district level 
then regional and followed lastly by tertiary. This is in line with the healthcare referral 
system in South Africa. The association between antibiotic selection pressures 
resulting in resistance is well documented and results from this study added to the 
body of knowledge that it is not a direct causal relationship. As recommended in the 
South African Antimicrobial Resistance Framework objectives there is the need for 
on-going surveillance that  will assist in creating a database for monitoring and 
evaluation of antibiotic consumption and its impact on the emergence and or changes 
to antibiotic resistance.  Such a database will additionally allow the early detection of 
outbreaks. Moreover, the dissemination of surveillance data to prescribers and policy 
makers will assist in improving antibiotic prescribing, provide evidence based 
antibiotic stewardship interventions and improve on current antibiotic guidelines 
tailored for hospitals based on their specific antibiotic consumption and susceptibility 
profiles. 
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CHAPTER 3. CONCLUSION 
 
3.1 Introduction 
 
Antibiotic consumption data for three hospitals at different levels of care were successfully 
converted into DDD/ 1000 inhabitants to express antibiotic consumption according to WHO 
recommendations. Antibiotic resistance data was presented as percentage susceptibility. 
Comparisons on antibiotic use and resistance were made between the different levels of 
health care (i.e. district, regional and tertiary). Yearly antibiotic consumption was correlated 
with yearly susceptibility trends to demonstrate the relationship between antibiotic use and 
resistance. 
 
The following were the main conclusions: 
 
 There was greater use (DDD/ 1000 inhabitants) of narrower spectrum antibiotics at 
the lower district and regional levels while broader spectrum antibiotics were more 
frequently used at the higher tertiary level of care. 
 Decreased antibiotic susceptibility was evident at higher levels of healthcare. 
  When yearly antibiotic consumption (DDD/1000 inhabitants) was correlated with 
antibiotic resistance patterns for both E. coli and S. aureus, antibiotics that were used 
frequently displayed higher resistance levels, however, a direct causal relationship 
could not be established 
 There is the need for on-going surveillance to create a database to generate an 
evidence base for interventions such as antibiotic guidelines based on hospital 
specific antibiotic use and susceptibility profiles.   
 
3.2 Limitations 
 
 To calculate DDD annual consumption depot data received from Provincial 
Department of Health for the years 2014 to 2016 was used. By using depot data, one 
is unable to determine whether the medication was in actual fact prescribed and/or 
administered.  
 Using catchment population data (DDD/1000 inhabitants) as a denominator resulted 
in a possible underestimation of antibiotic consumption. 
 There was no information available on the patients who received the antibiotics used. 
DDD gives us a quantitative idea regarding antibiotic use but no indication of the 
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quality of prescribing or whether the prescribed antibiotic was actually taken by the 
patient. DDD is a technical measurement to represent antibiotic use it does not 
necessarily reflect the recommended or average prescribed dose.  
 Confounding factors (i.e. infection prevention and control, invasive procedures in the 
hospital setting, patient history, disease profile and timely administration of 
antibiotics by nursing staff) do play a role in the emergence of resistance; however, 
they were not taken into account in this study. 
3.3 Recommendations 
 
The following recommendations are made based on the results of this study: 
 
 DDD should be used in the public sector across facilities to monitor antibiotic 
consumption as it allows for standardised comparisons to be made between 
institutions, nationally and internationally. 
 Monitoring sensitivity profiles in hospitals will assist in updating and improving 
hospital specific antibiotic guidelines. 
 Alternative denominators for quantification for example days of therapy (DOT) for 
each antibiotic should be explored. DOT provides a sum of days in which each 
antibiotic was administered. Length of therapy (LOT) – also known as antibiotic 
exposure time is the number of days that the patient received an antibiotic 
irrespective of the number of different antibiotics. Both DOT and LOT are measures 
for reporting antibiotic use using patient level data.  
 A study design that takes into consideration confounding factors that affect the 
emergence of resistance should be developed. 
3.4 Significance 
 
The WHO Antimicrobial Consumption (AMC) tool had been successfully used to calculate 
DDDs. This tool can be used in the hospital and community setting to capture antibiotic 
consumption as DDDs in order to monitor antibiotic stewardship programmes and to assess 
the impact of interventions aimed at reducing antibiotic consumption. By using WHO 
methodology to calculate antibiotic consumption it allows for comparisons to be made both 
nationally and internationally. Exploring trends between antibiotic consumption and 
susceptibility patterns showed, that to a certain extent, the relationship between antibiotic use 
and resistance can be correlated, bearing in mind that a direct causal relationship cannot be 
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deduced as there are confounding factors including but not limited to  different levels of care, 
infection and prevention control and patient and disease profiles.  
 
